Active ingredient prescribing – a winner?

Dr Linda Calabresi

writer

Dr Linda Calabresi

GP; Medical Editor, Healthed

Claim CPD for this activity

Educational Activities (EA)

0 hours

These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.

Reviewing Performance (RP)

0 hours

These are activities that require reflection on feedback about your work.

Measuring Outcomes (MO)

0 hours

These are activities that use your work data to ensure quality results.

EA
0 minutes

These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.

RP
0 minutes

These are activities that require reflection on feedback about your work.

MO
0 minutes

These are activities that use your work data to ensure quality results.

Dr Linda Calabresi

Despite being mooted for many years, active ingredient prescribing arrived in GPs’ script writing software with relatively little fanfare in February this year.

Now, regardless of what brand the doctor types in, the text on the printed script will give the active ingredient in essence, leaving the brand choice to the discretion of the pharmacist.

As well as the obvious motive of promoting generics and saving money, authorities also claimed active ingredient prescribing would help patients become more aware of their medicines and reduce confusion.

However, a recent Healthed survey suggests this goal is some way from being achieved.

According to the survey of more than 800 GPs around Australia, more than two thirds (68%) say that every week, they are having patients negatively impacted by this change. In fact, almost half say they are getting at least four patients a week, often many more, who have been disadvantaged in some way by this move.

And the negative impact is not solely being felt by the patients. The survey also revealed that the vast majority of GPs, almost 80%, found active ingredient prescribing frustrating with 12% reporting the scheme as being extremely frustrating.

It will be interesting to see what is being considered as markers of success when and if this prescribing initiative is evaluated by the powers that be.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
A/Prof Daryl Efron

A/Prof Daryl Efron

Autism Spectrum Disorder in Children

Dr Sonia Davison

Dr Sonia Davison

Early Menopause

Scientia Prof Henry Brodaty AO

Scientia Prof Henry Brodaty AO

Donanemab – A GP Guide to Anti-Amyloid Therapies

Prof Andrew Sindone

Prof Andrew Sindone

LDL and Cardiovascular Disease

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Share this

Share this

Dr Linda Calabresi

writer

Dr Linda Calabresi

GP; Medical Editor, Healthed

Test your knowledge

Recent articles

Latest GP poll

When do you plan to retire or leave general practice?

Within the next 12 months

0%

Within the next 3 years

0%

Within the next 5 years

0%

Within the next 10 years

0%

More than 10 years

0%

Recent podcasts

Listen to expert interviews.
Click to open in a new tab

Find your area of interest

Once you confirm you’ve read this article you can complete a Patient Case Review to earn 0.5 hours CPD in the Reviewing Performance (RP) category.

Select ‘Confirm & learn‘ when you have read this article in its entirety and you will be taken to begin your Patient Case Review.

Menopause and MHT

Multiple sclerosis vs antibody disease

Using SGLT2 to reduce cardiovascular death in T2D

Peripheral arterial disease